The effect of long-chain n-3 PUFA on the metabolism of apoB100-containing lipoprotein in diabetic subjects is not fully understood. The objective of the present study was to determine the effect of a daily intake of 1080mg EPA and 720mg DHA for diabetic subjects on the kinetics of apoB100-containing lipoprotein in the fasting state. A kinetic study was undertaken to determine the mechanisms involved in the effects of n-3 fatty acids in terms of a decrease in triacylglycerol level in type 2 diabetic patients. We have studied the effect of fish oils on the metabolism of apoB100 endogenously labelled by [5,5,5–2H3]-leucine in type 2 diabetic patients in the fasting state. The kinetic parameters of apoB100 in VLDL, intermediate-density lipoprotein and LDL were determined by compartmental modelling in five diabetic subjects before and 8 weeks aftern-3 fatty acid treatment. Treatment did not change the plasma cholesterol level (0·801 (sd 0·120)v. 0·793 (sd 0·163) mmol/l) but lowered the plasma triacylglycerol level (1·776 (sd 0·280) v.1·356 (sd 0·595) mmol/l; p<0·05). Treated patients showed a decrease in VLDL apoB100 concentration (0·366 (sd 0·030) v.0·174 (sd 0·036) g/l; v<0·05) related to a decrease in VLDL 1 production (1·49 (sd 0·23) v.0·44 (sd 0·19) mg/kg per h; p<0·05) and an increase in the VLDL conversion rate (0·031 (sd 0·024)v.0·052 (sd 0·040) per h; p<0·05), with no change in fractional catabolic rates. Treatment led to a higher direct production of intermediate-density lipoprotein (0·02 (sd 0·01) v 0·24 (sd 0·12) mg/kg per h; p<0·05). In conclusion, the present study, conducted in the fasting state, showed that supplementation with n-3 fatty acids in type 2 diabetic patients induced beneficial changes in the metabolism of apoB100-containing lipoprotein.